...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Debt

,,,,,,,,,,,,,,,,,I still cant understand these big name Pharmas which are in trial with Zen and still are not making attempts to take it out,,,,,,,,,,,,,,,,,

I see no reason why they would do a buyout now.  Makes total sense they would want to see the results of those trials first.  Otherwise, why do a trial?  They need to determine if it works, how well, and safety, in order to know what it's worth.

Which means, IMO, we have to wait until one or more trials are done, plus many more months for results, plus many more months for them to ponder and negotiate a deal.

 

Share
New Message
Please login to post a reply